UCB Pharma (VOGALENE And VOGALIB)
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Two medicinal products. The portfolio comprises of development, manufacturing, marketing and sale of Vogalib(R) and Vogalene(R) medicines. They are approved for use in the symptomatic treatment of nausea and vomiting. The injectible is approved for the prevention of nausea and vomiting in patients under chemotherapy.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Office
- France
UCB Pharma (VOGALENE And VOGALIB) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore UCB Pharma (VOGALENE And VOGALIB)‘s full profile, request access.
Request full access to PitchBookUCB Pharma (VOGALENE And VOGALIB) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore UCB Pharma (VOGALENE And VOGALIB)‘s full profile, request access.
Request full access to PitchBook